Guidant
This article was originally published in The Gray Sheet
Executive Summary
Firm files premarket approval application with FDA Feb. 28 for its Contak CD pulse generator and Easytrak lead for congestive heart failure. The Contak, which combines cardiac resynchronization capability with implantable defibrillation therapy, will be the first such device for CHF to be reviewed by the agency
You may also be interested in...
Medtronic MIRACLE Foreshadows Resynchronized Approach To CHF Therapy
A clear clinical benefit demonstrated by Medtronic's InSync atrial synchronous biventricular pacing system in treating congestive heart failure could give FDA the impetus to bring resynchronization therapy to panel review as early as June.
Medtronic MIRACLE Foreshadows Resynchronized Approach To CHF Therapy
A clear clinical benefit demonstrated by Medtronic's InSync atrial synchronous biventricular pacing system in treating congestive heart failure could give FDA the impetus to bring resynchronization therapy to panel review as early as June.
ICDs For Heart Failure: Technical Improvements Will Determine Uptake
FDA's decision to approve implantable defibrillators for congestive heart failure is likely to rest on reconciling its desire for mortality data, which will not be available for about two years, with quality-of-life data showing a benefit in some patients.